G protein-coupled receptor 55 activated by palmitoylethanolamide is associated with the development of nocturia associated with circadian rhythm disorders.

Circadian rhythm Fatty acid metabolite GPR55 Nocturia Palmitoylethanolamide

Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Nov 2023
Historique:
received: 23 05 2023
revised: 17 08 2023
accepted: 03 09 2023
pubmed: 14 9 2023
medline: 14 9 2023
entrez: 13 9 2023
Statut: ppublish

Résumé

Bladder function is regulated by clock genes and dysregulation of circadian bladder function can cause nocturia. The blood concentration of palmitoylethanolamide (PEA), a fatty acid metabolite, changes with circadian rhythm. Clock gene abnormalities demonstrate the highest PEA levels during the sleep phase. PEA is a GPR55 agonist that influences urination; therefore, increased PEA during the sleep phase may cause nocturia. Herein, we investigated the function of GPR55 to evaluate the relationship between GPR55 and nocturia that evoked higher PEA during the sleep phase in patients with circadian rhythm disorders. Male C57BL/6 mice were used. GPR55 localization was evaluated by immunofluorescence staining, qRT-PCR, and western blotting. Variations in PEA-induced intracellular Ca GPR55 was predominant in the UC layer. PEA induced release of Ca The loss of regular circadian metabolizing rhythm in fatty acids causes higher blood PEA levels during the sleep phase. Binding of PEA to GPR55 in UC may activate the downstream processes of the micturition reflex, leading to nocturia. These findings suggest a new mechanism for nocturia and its potential as a therapeutic target.

Identifiants

pubmed: 37704067
pii: S0024-3205(23)00707-5
doi: 10.1016/j.lfs.2023.122072
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122072

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that there are no conflict of interests.

Auteurs

Tatsuya Ihara (T)

Department of Urology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa 213-8587, Japan. Electronic address: tihara@toranomon.gr.jp.

Youichi Shinozaki (Y)

Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.

Eiji Shigetomi (E)

Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Yosuke Danjo (Y)

Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Sachiko Tsuchiya (S)

Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Mie Kanda (M)

Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Manabu Kamiyama (M)

Department of Urology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa 213-8587, Japan.

Masayuki Takeda (M)

Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Schuichi Koizumi (S)

Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Takahiko Mitsui (T)

Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.

Classifications MeSH